StockNews.AI
NTRB
StockNews.AI
49 days

Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index

1. Nutriband joins multiple Russell indexes, enhancing visibility and credibility. 2. CEO emphasizes AVERSA Fentanyl's potential sales of $80M to $200M. 3. Russell indexes benchmark $10.6 trillion in assets, spotlighting NTRB's importance. 4. AVERSA technology features patented solutions for safer medication use. 5. FTSE Russell aims to adapt indexes for better market representation.

8m saved
Insight
Article

FAQ

Why Bullish?

Being added to major Russell indexes often leads to increased investment interest and stock demand, evident in the stock performance of similar companies during index reconstitutions.

How important is it?

NTRB's inclusion in key indexes significantly elevates its marketplace visibility and can attract institutional investors, providing liquidity and potential stock appreciation.

Why Short Term?

The immediate boost from index inclusion typically occurs during reconstitution events, which leads to immediate stock upticks, though long-term performance depends on product development.

Related Companies

NTRBWSPYIWM
ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth Indexes, as part of the 2025 Russell indexes reconstitution. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. “Being added to the four Russell indexes is a great honor for us as a company as we continue to strive towards building shareholder value and progressing the development of our AVERSA pipeline and in particular AVERSA Fentanyl which has the potential to reach peak annual US sales of $80 million to $200 million. We believe our addition now reflects a market focus on us as a company and the momentum we are building to revolutionize the safety profile of easily abused medications while making these medications available to those in need as a result,” said Gareth Sheridan, CEO of Nutriband Inc. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell’s US indexes serve as the benchmark for about $10.6 trillion in assets as of the close of June 2024. Russell indexes are part of FTSE Russell, the global index provider. Fiona Bassett, CEO of FTSE Russell, An LSEG business, comments: “The Russell indexes have continuously adapted to the evolving dynamic US economy, and it’s crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.” For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release. About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group.  For more information, visit FTSE Russell. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information: Nutriband Inc.Phone: 407-377-6695Email: info@nutriband.com SOURCE: Nutriband Inc.

Related News